NASDAQ:ANIP - ANI Pharmaceuticals Inc Common Stock Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$56.41 +0.59 (+1.06 %)
(As of 08/20/2018 04:55 AM ET)
Previous Close$56.41
Today's Range$55.03 - $56.47
52-Week Range$44.97 - $74.70
Volume76,237 shs
Average Volume109,413 shs
Market Capitalization$672.84 million
P/E Ratio15.63
Dividend YieldN/A
Beta2.78
ANI Pharmaceuticals Inc Common Stock logoANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANIP
CUSIPN/A
Phone218-634-3500

Debt

Debt-to-Equity Ratio1.08
Current Ratio3.84
Quick Ratio2.89

Price-To-Earnings

Trailing P/E Ratio15.63
Forward P/E Ratio12.56
P/E GrowthN/A

Sales & Book Value

Annual Sales$176.84 million
Price / Sales3.77
Cash Flow$5.9192 per share
Price / Cash9.53
Book Value$14.99 per share
Price / Book3.76

Profitability

EPS (Most Recent Fiscal Year)$3.61
Net Income$-1,070,000.00
Net Margins0.06%
Return on Equity27.76%
Return on Assets12.34%

Miscellaneous

Employees173
Outstanding Shares11,830,000
Market Cap$672.84 million

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Frequently Asked Questions

What is ANI Pharmaceuticals Inc Common Stock's stock symbol?

ANI Pharmaceuticals Inc Common Stock trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals Inc Common Stock's earnings last quarter?

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) announced its quarterly earnings data on Tuesday, August, 7th. The specialty pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.34 by $0.21. The specialty pharmaceutical company had revenue of $47.27 million for the quarter, compared to analysts' expectations of $50.70 million. ANI Pharmaceuticals Inc Common Stock had a net margin of 0.06% and a return on equity of 27.76%. View ANI Pharmaceuticals Inc Common Stock's Earnings History.

When is ANI Pharmaceuticals Inc Common Stock's next earnings date?

ANI Pharmaceuticals Inc Common Stock is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for ANI Pharmaceuticals Inc Common Stock.

What guidance has ANI Pharmaceuticals Inc Common Stock issued on next quarter's earnings?

ANI Pharmaceuticals Inc Common Stock updated its FY18 earnings guidance on Tuesday, August, 7th. The company provided earnings per share (EPS) guidance of $4.80-5.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.74. The company issued revenue guidance of $195-205 million, compared to the consensus revenue estimate of $215.60 million.

What price target have analysts set for ANIP?

2 equities research analysts have issued 12-month price objectives for ANI Pharmaceuticals Inc Common Stock's shares. Their predictions range from $74.00 to $75.00. On average, they expect ANI Pharmaceuticals Inc Common Stock's stock price to reach $74.50 in the next year. This suggests a possible upside of 32.1% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals Inc Common Stock.

What is the consensus analysts' recommendation for ANI Pharmaceuticals Inc Common Stock?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals Inc Common Stock in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals Inc Common Stock.

Who are some of ANI Pharmaceuticals Inc Common Stock's key competitors?

Who are ANI Pharmaceuticals Inc Common Stock's key executives?

ANI Pharmaceuticals Inc Common Stock's management team includes the folowing people:
  • Mr. Arthur S. Przybyl, CEO, Pres & Director (Age 61)
  • Mr. Stephen P. Carey, CFO & VP of Fin. (Age 47)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 55)
  • Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 46)
  • Dr. David J. Sullivan, VP of Quality Operations

Has ANI Pharmaceuticals Inc Common Stock been receiving favorable news coverage?

News articles about ANIP stock have trended somewhat positive on Monday, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ANI Pharmaceuticals Inc Common Stock earned a coverage optimism score of 0.20 on Accern's scale. They also gave headlines about the specialty pharmaceutical company an impact score of 46.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for ANI Pharmaceuticals Inc Common Stock.

Who are ANI Pharmaceuticals Inc Common Stock's major shareholders?

ANI Pharmaceuticals Inc Common Stock's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.79%), Dimensional Fund Advisors LP (4.06%), Nomura Holdings Inc. (2.63%), LSV Asset Management (2.55%), Renaissance Technologies LLC (1.47%) and Schwab Charles Investment Management Inc. (0.71%). Company insiders that own ANI Pharmaceuticals Inc Common Stock stock include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals Inc Common Stock.

Which major investors are selling ANI Pharmaceuticals Inc Common Stock stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Algert Global LLC, Raymond James & Associates, Bank of America Corp DE, Dana Investment Advisors Inc., BlueMountain Capital Management LLC, LaSalle Street Capital Management LLC and Renaissance Technologies LLC. Company insiders that have sold ANI Pharmaceuticals Inc Common Stock company stock in the last year include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Insider Buying and Selling for ANI Pharmaceuticals Inc Common Stock.

Which major investors are buying ANI Pharmaceuticals Inc Common Stock stock?

ANIP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Boston Partners, Phocas Financial Corp., American Century Companies Inc., Rice Hall James & Associates LLC, Nomura Holdings Inc., Mackay Shields LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for ANI Pharmaceuticals Inc Common Stock.

How do I buy shares of ANI Pharmaceuticals Inc Common Stock?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals Inc Common Stock's stock price today?

One share of ANIP stock can currently be purchased for approximately $56.41.

How big of a company is ANI Pharmaceuticals Inc Common Stock?

ANI Pharmaceuticals Inc Common Stock has a market capitalization of $672.84 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals Inc Common Stock employs 173 workers across the globe.

How can I contact ANI Pharmaceuticals Inc Common Stock?

ANI Pharmaceuticals Inc Common Stock's mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]


MarketBeat Community Rating for ANI Pharmaceuticals Inc Common Stock (NASDAQ ANIP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals Inc Common Stock and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel